Research Reports

Key takeaways

Nasdaq notified Rockwell Medical of non-compliance with the $1.00 minimum bid price rule on May 8, 2026.

The company has 180 calendar days, until November 4, 2026, to regain compliance.

To regain compliance, the stock must close at $1.00 or more for at least ten consecutive business days.

Rockwell Medical plans to propose a reverse stock split at its 2026 annual meeting to address the deficiency.

There is no immediate impact on the listing or trading of the common stock on Nasdaq.

Failure to regain compliance could lead to delisting, though additional time may be available.

Full analysis

Rockwell Medical, Inc. received a written notice from Nasdaq on May 8, 2026, indicating that the company's common stock failed to meet the minimum bid price requirement of $1.00 per share for 30 consecutive business days. This triggers a 180-calendar day compliance period ending November 4, 2026, during which the stock will continue to trade on The Nasdaq Capital Market. To regain compliance, the closing bid price must be at least $1.00 for ten consecutive business days. The company has disclosed that it is seeking shareholder approval for a reverse stock split at its 2026 Annual Meeting, which, if implemented, is expected to cure the deficiency. However, there is no assurance that the reverse split will be approved or that compliance will be achieved. This event is material as it directly impacts the company's listing status and could lead to delisting if not resolved, potentially affecting liquidity and investor confidence.

RMTI · Rockwell Medical, Inc.

Summary

Key takeaways

Full analysis